Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Immunic, Inc. (IMUX)

5.02   -0.07 (-1.38%) 08-18 06:18
Open: 5.06 Pre. Close: 5.09
High: 5.23 Low: 5
Volume: 67,909 Market Cap: 153(M)
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.23 - 5.27 5.27 - 5.3
Low: 4.93 - 4.97 4.97 - 5
Close: 4.97 - 5.03 5.03 - 5.07

Technical analysis

as of: 2022-08-17 4:24:18 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.45     One year: 7.54
Support: Support1: 4.14    Support2: 3.28
Resistance: Resistance1: 5.53    Resistance2: 6.45
Pivot: 4.61
Moving Average: MA(5): 5.15     MA(20): 4.37
MA(100): 5.72     MA(250): 8.36
MACD: MACD(12,26): 0.3     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 85.2     %D(3): 87.2
RSI: RSI(14): 58.8
52-week: High: 14.5  Low: 2.51
Average Vol(K): 3-Month: 732 (K)  10-Days: 196 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IMUX ] has closed below upper band by 36.1%. Bollinger Bands are 11.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 16 Aug 2022
Short Interest in Immunic, Inc. (NASDAQ:IMUX) Declines By 9.5% - MarketBeat

Tue, 16 Aug 2022
Immunic Inc. (IMUX) Granted Notice of Allowance for Composition-of-Matter Patent in US for IMU-856 -

Sat, 06 Aug 2022
Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Thu, 04 Aug 2022
Immunic Inc. Tops Q2 EPS by 1c By -

Thu, 04 Aug 2022
Immunic: Q2 Earnings Snapshot - CTPost

Wed, 15 Jun 2022
Immunic (IMUX) Stock Price: Why It Increased Over 4% Today - Pulse 2.0

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 31 (M)
Shares Float 16 (M)
% Held by Insiders 17.3 (%)
% Held by Institutions 58.3 (%)
Shares Short 1,160 (K)
Shares Short P.Month 1,900 (K)

Stock Financials

EPS -3.12
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.88
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -37.4
Return on Equity (ttm) -67
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.69
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -1.61
PEG Ratio -0.1
Price to Book value 0.85
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-04-14
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.